An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Opthea Limited (CKDXF – Research Report) received a Sell rating and a A$0.05 price target from Bell Potter analyst Thomas Wakim yesterday. The ...